A Prospective Observational Identification of the Most Common Etiologies and the Frequent Stage of Presentation in Patients with Neovascular Glaucoma
Authors/Creators
- 1. Assistant Professor, Department of Ophthalmology, Patna Medical College and Hospital, Patna, Bihar, India
- 2. Senior Resident, Department of Ophthalmology, Patna Medical College and Hospital, Patna, Bihar, India
Description
Aim: To identify the most common cause and the frequent stage of presentation in patients with neovascular glaucoma. Material & Methods: The present study is a prospective observational study, 460 patients with Glaucoma of multiple type and of etiology underwent detail ophthalmological examination and 16 case those have been diagnosed as neovascular glaucoma (NVG) in one eye or both the eyes at Department of ophthalmology, Patna Medical College and Hospital, Patna, Bihar, India over a period of 13 months were included in the study, with prevalence of 3.5% of all glaucoma cases. Results: Most of the patients i.e., 11 (68.8%) presented in rubeosis iridis stage, 3 (18.75%) in open angle stage and 02 (12.5%) in angle closure stage. The Mean IOP in Angle closure stage was found significantly higher than the mean IOP in other two stages (P = 0.001). Conclusion: In the present study, it was found although prevalence of NVG is significantly low among cases of all glaucoma but the rising trend of Diabetic in population is of concern and this study also confirms that more than half of the cases of NVG were found with Proliferative diabetic retinopathy is the most common cause and rubeosis iridis stage was the commonest finding.
Abstract (English)
Aim: To identify the most common cause and the frequent stage of presentation in patients with neovascular glaucoma. Material & Methods: The present study is a prospective observational study, 460 patients with Glaucoma of multiple type and of etiology underwent detail ophthalmological examination and 16 case those have been diagnosed as neovascular glaucoma (NVG) in one eye or both the eyes at Department of ophthalmology, Patna Medical College and Hospital, Patna, Bihar, India over a period of 13 months were included in the study, with prevalence of 3.5% of all glaucoma cases. Results: Most of the patients i.e., 11 (68.8%) presented in rubeosis iridis stage, 3 (18.75%) in open angle stage and 02 (12.5%) in angle closure stage. The Mean IOP in Angle closure stage was found significantly higher than the mean IOP in other two stages (P = 0.001). Conclusion: In the present study, it was found although prevalence of NVG is significantly low among cases of all glaucoma but the rising trend of Diabetic in population is of concern and this study also confirms that more than half of the cases of NVG were found with Proliferative diabetic retinopathy is the most common cause and rubeosis iridis stage was the commonest finding.
Files
IJPCR,Vol14,Issue6,Article110.pdf
Files
(117.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:b6f013443daa9364b18330f7a5a77614
|
117.6 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-06-20
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/14/IJPCR,Vol14,Issue6,Article110.pdf
- Development Status
- Active
References
- 1. Latina MA, Shazly TA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 2009; 24: 113-121. 2. Parrish R, Hershler J. Eyes with endstage neovascular glaucoma. Natural history following successful modified filtering operation. Arch Ophthalmol.1983;101(5):745-6. 3. Beutel J, Peters S, Lüke M, Aisenbrey S, Szurman P, Spitzer MS, Yoeruek E; Bevacizumab Study Group, Grisanti S. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol. 2010;88(1):103-9. Comment in Acta Ophthalmol. 2010;88(4):e133. 4. Douat J, Auriol S, Mahieu-Durringer L, Ancèle E, Pagot-Mathis V, Mathis A. [Intravitrealbevacizumab for treatment of neovascular glaucoma. Report of 20 cases]. J FrOphtalmol. 2009;32(9):652-63. 5. Olmos LC, Lee RK. Medical and surgical treatment of neovascular glaucoma. IntOphthalmolClin 2011; 51(3): 27–36. 6. Cashwell LF, Marks WP. Panretinal photocoagulation in the management of neovascular glaucoma. South Med J 1988; 81(11): 1364–1368. 7. Hayreh SS, Klugman MR, Podhajsky P, Servais GE, Perkins ES. Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study. Graefes Arch ClinExpOphthalmol 1990; 228(4): 281–296 8. Sivak-Callcott JA, O'Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001; 108(10): 1767– 1776. 9. Doft BH, Blankenship G. Retinopathy risk factor regression after laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1984;91(12): 1453– 1457. 10. Tamura T. Electron microscopic study on the small blood vessels in rubeosisiridisdiabetica. J Japanese Ophthalmol Soc. 1968;72(11):2340– 2352. 11. Vannas A. Fluorescein angiography of the vessels of the iris in pseudoeexfoliation of the lens capsule, capsular glaucoma, and some other forms of glaucoma. ActaOphthalmol Suppl. 1969; 105:1–75. 12. John T, Sassani JW, Eagle RC. The Myofibroblastic Component of RubeosisIridis. Ophthalmol. 1983;90(6):721–728. 13. Duker JS, Brown GC. The efficacy of panretinal photocoagulation forneovascularization of the iris after central retinal artery obstruction. Ophthalmology 1989; 96(1):92–95. 14. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/ panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008; 28(5): 696–702. 15. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115(9): 1571–1580. 1580.e1–e3. 16. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitrealbevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in41 consecutive cases. Ophthalmology 2008; 115:1571-80,15 80.e1-3. 17. Vancea PP, Abu-Taleb A. Current trends in neovascular glaucoma treatment. Rev Med ChirSoc Med Nat Iasi. 2005;109(2):264–268. 18. Haefliger IO, Zschaner A, Anderson DR. Relaxation of retinal pericyte contractile tone through the nitric oxide cyclic guanosine monophosphate pathway. Invest Opth Vis Sci. 1994;35(3):991–997. 19. Pérez, A. D., Valle, D. M., Medina L. C. G., Burgos R. A. O., Reyes, J. D. S., Solano O. I. A., Anguila J. J. M., & Rojas M. F. R. Assisted Therapy with Vacuum and Floating Stoma: A New Way to Treat a Periostomal Abscess. Journal of Medical Research and Health Sciences, 2021: 4(12), 1629– 1635. 20. Ringvold A, Davanger M. Iris neovascularisation in eyes with pseudoexfoliation syndrome. British Journal of Ophthalmology. 1981;65 (2) :138–141. 21. Brooks AMV, Gillies WE. The Development of Microneovascular Changes in the Iris in Pseudoex foliation of the Lens Capsule. Ophthalmol. 1987;94(9):1090–1097. 22. Sharma P, Agarwal N, Choudhry RM. Neovascular Glaucoma - A Review. Delhi J Ophthalmol. 2016;26(3):170– 175.